(Boursier.com) – Mauna Kia Technologies A new meta-analysis, “Review of High-Resolution Probe-Based Confocal Laser Microscopy and a Meta-Analysis for Detecting Tumors in Barrett’s Esophagus”, is published in Technologies and Innovations in Gastrointestinal Endoscopy (TIGE), a peer-reviewed journal.
The study demonstrates that adding microscopy using Cellvizio as an adjunct to guide biopsies provides a significantly higher diagnostic yield for dysplasia and cancer and reduces sampling error compared to randomized 4-quartile biopsies alone, constituting the standard method for diagnosis.
In addition, during the ENDO 2022 World Congress of Gastrointestinal Endoscopy, results of a retrospective, multicenter study of the records of 60 patients with Barrett’s esophagus who were referred for observation or endoscopic therapy were presented. The authors examined differences in gastroenterology health services use of eight items/services among patients imaged with Cellvizio as an adjunct to standard diagnosis alone. La cohorte Cellvizio a obtenu des scores moindres de l’ordre de : 1.04 endoscopie et service d’anesthésie de moins, 7.49 flacons de biopsie de moins, 1.30 ablation de moins, et 1.46 service de brosses cytologiques at least. Thus, the researchers concluded that Cellvizio is associated with a lower overall burden on the healthcare system.
“The results of these studies show that there are better tools readily available to clinicians that can improve the detection rate of screening and surveillance programmes, and ultimately reverse the alarming rise in the prevalence of breast and esophageal cancer,” said Nicolas Bouvier, interim CEO. Mona Kia Technologies. “Better detection rates and lower healthcare utilization make Cellvizio a valuable addition to the standard diagnostic method in hospitals and outpatient surgery centers.”
© 2022 Boursier.com